Glycidaldehyde, a bifunctional carcinogenic alkylating agent, has been found to react with calf thymus DNA in vitro under alkaline conditions. A product was isolated and identified to be the result of a fusion of a delta4-imidazoline ring to the pyrimidine ring of deoxyguanosine at the N-1 and 2-NH2 positions. Following reaction and dialysis, the DNA was hydrolyzed enzymatically to nucleosides. The structural assignment of the product was based on comparison of the elution volume from a Sephadex G-10 column, the ultraviolet spectra at various conditions of pH, and the thin layer chromatographic properties with respect to an authentic sample. The formation of the extended ring system with DNA-derived guanosine may be related to the mode of carcinogenic action of this difunctional alkylating agent.

Download full-text PDF

Source

Publication Analysis

Top Keywords

alkylating agent
8
reaction dna
4
dna glycidaldehyde
4
glycidaldehyde isolation
4
isolation identification
4
identification deoxyguanosine
4
deoxyguanosine reaction
4
reaction product
4
product glycidaldehyde
4
glycidaldehyde bifunctional
4

Similar Publications

Introduction: Graft-versus-host disease (GvHD) remains a major complication of allogeneic stem cell transplantation (allo-SCT), affecting 30-70% of patients (representing 800 new patients per year in the UK). The risk is higher in patients undergoing unrelated allo-SCT. About 1 in 10 patients die as a result of GvHD or through complications of its treatment.

View Article and Find Full Text PDF

Noncanonical inhibition of topoisomerase II alpha by oxidative stress metabolites.

Redox Biol

January 2025

University of Chicago, Department of Molecular Genetics and Cell Biology, 929 E. 57th Street, Chicago, IL, 60637, USA. Electronic address:

During its catalytic cycle, the homodimeric ATPase topoisomerase II alpha (TOP2A) cleaves double stranded DNA and remains covalently bound to 5' ends via tyrosine phosphodiester bonds. After passing a second, intact duplex through, TOP2A rejoins the break and releases from the DNA. Thereby, TOP2A can relieve strain accumulated during transcription, replication and chromatin remodeling and disentangle sister chromatids for mitosis.

View Article and Find Full Text PDF

Co-Delivery of Dacarbazine and miRNA 34a Combinations to Synergistically Improve Malignant Melanoma Treatments.

Drug Des Devel Ther

January 2025

Department of Pharmaceutical Analysis, Higher Educational Key Laboratory for Nano Biomedical Technology of Fujian Province, The School of Pharmacy, Fujian Medical University, Fuzhou, 350122, People's Republic of China.

Purpose: The incidence of malignant melanoma (MM) has risen over the past three decades, and despite advancements in treatment, there is still a need to improve treatment modalities. This study developed a promising strategy for tumor-targeted co-delivery of Dacarbazine (DTIC) and miRNA 34a-loaded PHRD micelles (Co-PHRD) for combination treatment of MM.

Methods: To construct the dual drug-loaded delivery system Co-PHRD, poly (L-arginine)-poly (L-histidine)-polylactic acid (PLA) was employed as a building block.

View Article and Find Full Text PDF

Tumour cells possess a multitude of chemoresistance mechanisms, which could plausibly contribute to the ineffectiveness of chemotherapy. O-methylguanine-DNA methyltransferase (MGMT) is an important effector protein associated with Temozolomide (TMZ) resistance in various tumours. To some extent, the expression level of MGMT determines the sensitivity of cells to TMZ, but the mechanism of its expression regulation has not been fully elucidated.

View Article and Find Full Text PDF

Objectives: Hepatocellular carcinoma (HCC) represents the third-most prevalent cancer in humans worldwide. The current study's objective is to search for the potentiality of H. Wendl () leaf extract in a nanoemulsion (NE) form in enhancing radiotherapy against HCC induced in rats using diethylnitrosamine (DEN).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!